Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS

Posted by Chantel Martiromo, research contributed by PubMed 
In a randomised placebo-controlled study of thirty overweight/obese women with PCOS (body mass index>25 kg/m(2), mean age 29.1+/- 1.2 (S.E.M.) years) randomly allocated to either rosiglitazone (Avandia, 4 mg twice a day) or placebo treatment and to assess of plasma levels of adiponectin, resistin and ghrelin and their correlation to serum levels of insulin, C-peptide and steroid hormones, and insulin sensitivity (euglycaemic hyperinsulinaemic clamp), posted in PubMed, found that Rosiglitazone had beneficial effects on serum levels of adiponectin and resistin, suggesting that these adipocytokines may contribute to the improvement in insulin sensitivity observed during the treatment.

Chinese Secrets to Fatty Liver and Obesity Reversal
A fabulous E book with Research based & Scientifically proven Efficacy To Treat Fatty Liver Diseases & Achieve Optimal Health & Loose Weight
 
Back to hormones http://medicaladvisorjournals.blogspot.ca/p/hormones.html

Back to Obesity and Complications